Skip to content
RKWD
ROCKWOOD RESEARCH · A CORPORATE FILINGS WEBSITE|STRAIGHT FROM THE SOURCE · SEC EDGAR|SPONSOREDYour message on this tape — bid on the Rockwood Ad Exchange · Rockwood Ad Exchange|
Rockwood Research
…

BCRX

BIOCRYST PHARMACEUTICALS INC

Biological Products, (No Diagnostic Substances) · SIC 2836CIK 882796Held by 6 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:XLINKEDINEMAIL
Revenue FY2025
$875.0M
Net Income FY2025
$264.0M
EPS (Basic, as reported)
$1.26
Net Margin FY2025
30.2%
ROE FY2025
-221.4%
Total Equity
$(119.0M)
Shares Out
256M
Business description

BIOCRYST PHARMACEUTICALS INC — Biological Products, (No Diagnostic Substances). Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2009–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions
i
default rows · click any row to chart itRevenue: 26 → 875 +47.8% CAGR
Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue2625214918157271331451875
Cost of revenue(2)(1)—(4)(2)(7)(6)(4)(12)(19)
Research & development(61)(67)(85)(107)(123)(209)(253)(217)(175)(166)
Selling, general & administrative(11)(14)(30)(37)(68)(119)(159)(214)(266)(349)
General & administrative——————————
Total operating expenses(75)(83)(115)(148)(193)(335)(419)(435)(453)(534)
Operating income(49)(57)(94)(99)(175)(178)(148)(104)(3)341
Interest expense(6)(9)(9)(12)(15)(59)(99)(108)(99)(79)
Other income (expense), net——————(96)(123)(84)(74)
Pre-tax income———(109)(183)(182)(244)(226)(87)267
Income tax expense00000(2)(3)0(2)(4)
Net income(55)(66)(101)(109)(183)(184)(247)(227)(89)264
EPS — basic————($1.09)($1.03)($1.33)($1.18)($0.43)$1.26
EPS — diluted————($1.09)($1.03)($1.33)($1.18)($0.43)$1.21
Shares outstanding — basic (M)————167179186192207210
Shares outstanding — diluted (M)7484103116167179186192207219

Showing the latest 10 of 17 fiscal years.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.